The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the use of investigational convalescent plasma to treat serious coronavirus patients.
The convalescent plasma is an antibody-rich blood component taken from people who have recovered from the COVID-19 infections. The FDA gave the authorization based on the scientific evidence available that the potential benefits of the product outweigh the known and potential risks of the product.
The evidence so far has been inconclusive about whether it works, when to administer it, and what dose is required.
Interested in Intellizence Demo?
Intellizence is an award-winning AI-powered business signal intelligence platform, that helps you to discover sales and risk signals in target companies as well as stay informed about emerging industry trends and regulatory changes.
Identify Emerging Opportunities & Risks